Widening the Aperture; New Approaches for Immunotherapy in Prostate Cancer

Session 10: Widening the Aperture; New Approaches for Immunotherapy in Prostate Cancer
Friday, November 5, 2021 | 8:50 AM – 10:35 AM PST

Moderator: Amy Moran, PhD, Oregon Health & Science University

A T Cell Intrinsic Role for Androgen Receptor Signaling and Immunotherapy Resistance
Amy Moran, PhD, Oregon Health & Science University

Checkpoint Immunotherapy in mCRPC with CDK12-Loss
Ajjai Alva, MD, University of Michigan

MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in Patients With mCRPC: Preliminary Results of Phase 1 Cohort Expansion
Chet Bohac, PharmD, MD, MSc, MacroGenics, Inc.

Targeting DLL3 with a Bi-Specific T Cell Engager: AMG 757 in De Novo and Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
Rahul Aggarwal, MD, University of California, San Francisco

Advancing the Frontiers of T-Cell Redirecting Agents in Prostate Cancer
Oliver Sartor, MD, Tulane University